The University of Chicago Header Logo

Connection

Michael Charlton to Hepatitis C

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Hepatitis C.
Michael Charlton
Connection Strength
10.133
Hepatitis C
  1. The Authors' Reply: Geographic Variation in the Utilization of HCV-viremic Donors Into HCV-negative Recipients. Transplantation. 2022 02 01; 106(2):e166.
    View in: PubMed
    Score: 0.694
  2. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.663
  3. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol. 2015 Aug; 110(8):1126-33.
    View in: PubMed
    Score: 0.430
  4. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
    View in: PubMed
    Score: 0.425
  5. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.418
  6. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr; 60(4):691-8.
    View in: PubMed
    Score: 0.394
  7. How important is acute cellular rejection? Liver Transpl. 2013 Nov; 19 Suppl 2:S9-13.
    View in: PubMed
    Score: 0.392
  8. Interleukin-28B polymorphism in hepatitis C and liver transplantation. Liver Transpl. 2013 Jan; 19(1):49-58.
    View in: PubMed
    Score: 0.370
  9. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012 Sep; 18(9):1029-36.
    View in: PubMed
    Score: 0.361
  10. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012 Jul 27; 94(2):197-203.
    View in: PubMed
    Score: 0.359
  11. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012 Mar; 18(3):323-31.
    View in: PubMed
    Score: 0.349
  12. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13.
    View in: PubMed
    Score: 0.289
  13. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
    View in: PubMed
    Score: 0.273
  14. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep. 2007 Mar; 9(1):23-30.
    View in: PubMed
    Score: 0.247
  15. Recurrence of hepatitis C infection: Where are we now? Liver Transpl. 2005 Nov; (11 Suppl 2):S57-62.
    View in: PubMed
    Score: 0.225
  16. Retransplantation for HCV--the view through a broken crystal ball. Liver Transpl. 2005 Apr; 11(4):382-3.
    View in: PubMed
    Score: 0.216
  17. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004 Sep; 10(9):1120-30.
    View in: PubMed
    Score: 0.208
  18. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir. 2003 Oct; 58(5):717-24.
    View in: PubMed
    Score: 0.195
  19. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.195
  20. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl. 2002 Oct; 8(10 Suppl 1):S50-4.
    View in: PubMed
    Score: 0.182
  21. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl. 2002 Sep; 8(9):814-21.
    View in: PubMed
    Score: 0.181
  22. Patient and graft survival following liver transplantation for hepatitis C: much ado about something. Gastroenterology. 2002 Apr; 122(4):1162-5.
    View in: PubMed
    Score: 0.176
  23. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.176
  24. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002 Apr; 8(4):362-9.
    View in: PubMed
    Score: 0.176
  25. Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl. 2002 Jan; 8(1):47-9.
    View in: PubMed
    Score: 0.173
  26. Hepatitis C infection in liver transplantation. Am J Transplant. 2001 Sep; 1(3):197-203.
    View in: PubMed
    Score: 0.169
  27. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
    View in: PubMed
    Score: 0.159
  28. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation. 2000 Jul 27; 70(2):292-7.
    View in: PubMed
    Score: 0.156
  29. Genotype 1b and severity of posttransplant recurrence of hepatitis C infection- unconvictable felon or wrongly accused? Liver Transpl. 2000 Mar; 6(2):243-5.
    View in: PubMed
    Score: 0.152
  30. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999 Jul; 5(4 Suppl 1):S107-14.
    View in: PubMed
    Score: 0.145
  31. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998 Sep; 28(3):823-30.
    View in: PubMed
    Score: 0.137
  32. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017 Nov; 17(11):2790-2802.
    View in: PubMed
    Score: 0.126
  33. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
    View in: PubMed
    Score: 0.125
  34. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
    View in: PubMed
    Score: 0.125
  35. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.124
  36. Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
    View in: PubMed
    Score: 0.118
  37. Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26(8):788-94.
    View in: PubMed
    Score: 0.095
  38. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.095
  39. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011 Jul; 54(1):3-5.
    View in: PubMed
    Score: 0.083
  40. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl. 2011 Jun; 17(6):723-32.
    View in: PubMed
    Score: 0.083
  41. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.082
  42. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010 Jun; 10(6):1420-7.
    View in: PubMed
    Score: 0.077
  43. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010 Jul; 53(1):199-206.
    View in: PubMed
    Score: 0.076
  44. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53.
    View in: PubMed
    Score: 0.064
  45. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006 Sep; 12(9):1381-9.
    View in: PubMed
    Score: 0.060
  46. Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2005 Oct; 11(10):1207-13.
    View in: PubMed
    Score: 0.056
  47. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology. 1999 Apr; 29(4):1220-6.
    View in: PubMed
    Score: 0.036
  48. Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol. 2005 Apr; 100(4):874-8.
    View in: PubMed
    Score: 0.014
  49. Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol. 2002 Apr; 33(4):435-6.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.